文献速递神经免疫

多发性硬化疾病修正治疗使用中的性别差异

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
PubMed 文献 · Neurology · 2025-07-30

基于法国多发性硬化观察登记处22,657例18-40岁起病的复发缓解型MS患者的回顾性队列研究,发现女性接受疾病修正治疗(DMT)的年度概率显著低于男性(OR 0.92,95%CI 0.87-0.97),接受高效DMT(HEDMT)的概率也更低(OR 0.80,95%CI 0.74-0.86)。差异在起病后2年(DMT)和1年(HEDMT)出现,且不随年龄变化。从5,268名女性的首次分娩分析,治疗比例在分娩前18个月开始下降,从42.6%降至受孕估计时的27.9%。

要点

  • 女性MS患者接受DMT和HEDMT的概率均显著低于男性。
  • 治疗差异在起病后1-2年出现,不随患者年龄变化。
  • 分娩前18个月起治疗比例下降,提示妊娠预期影响治疗决策。

核心结论

  • 女性MS患者接受DMT和HEDMT的概率显著低于男性,妊娠预期和性别特异性治疗惰性可能是重要原因。

研究设计与样本

  • 回顾性队列研究,数据来自2023年6月提取的法国多发性硬化观察登记处,纳入18-40岁起病的复发缓解型MS患者22,657例,女性16,857例(74.4%),起病平均年龄29.0(6.0)岁,中位随访11.6(6.6-17.3)年。

主要发现

  • 女性接受DMT的OR为0.92(95%CI 0.87-0.97),接受HEDMT的OR为0.80(95%CI 0.74-0.86)。
  • DMT的性别差异在起病后2年出现,HEDMT的差异在起病后1年出现,且不随患者年龄显著变化。
  • 特立氟胺、鞘氨醇-1-磷酸受体调节剂和抗CD20单抗在女性整个可用期间均显著使用不足。
  • 干扰素β和那他珠单抗初期在女性中使用较少,一段时间后趋于相等;醋酸格拉替雷和富马酸类初期相等,之后女性使用更频繁。
  • 从5,268名女性的首次分娩分析,治疗比例在分娩前18个月开始下降,从42.6%降至受孕估计时的27.9%。

临床怎么用

  • 神经科医生应依据最新妊娠期DMT使用推荐,与患者充分沟通,避免因妊娠预期导致治疗不足。

局限性

  • 本研究为回顾性队列研究,数据来自单一国家登记处,可能存在未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In women with multiple sclerosis (MS), the therapeutic strategy may be influenced by the anticipation of future pregnancies, leading to underexposure to disease-modifying therapies (DMTs) and highly effective DMTs (HEDMTs) compared with men. We aimed to evaluate potential therapeutic inertia in women with MS and explore its causes. METHODS: We performed a retrospective cohort study based on data extracted on June 2023 from the Observatoire Français de la Sclérose en Plaques for all patients with a relapsing-remitting MS onset between 18 and 40 years. The primary outcome was the annual probability of receiving a DMT, accounting for sex, disease severity, and pregnancy/postpartum periods. Secondary outcomes were the annual probability of receiving a HEDMT, each DMT separately, and interaction of the effect of sex with calendar year, patient age, and disease duration. We used a longitudinal logistic model with generalized estimating equations and an inverse-probability-of-censoring weighting. RESULTS: We included 22,657 patients with MS; 16,857 (74.4%) were female, mean (SD) age at onset was 29.0 (6.0) years, and median (interquartile range) follow-up duration was 11.6 (6.6-17.3) years. Women were significantly less likely to receive a DMT (odds ratio [OR] 0.92, 95% CI 0.87-0.97) or a HEDMT (OR 0.80, 95% CI 0.74-0.86). This difference appeared 2 years after disease onset for DMTs and 1 year for HEDMTs, and did not differ significantly according to patient's age. Teriflunomide, sphingosine-1-phosphate receptor modulators, and anti-CD20s were significantly underused in women throughout their entire period of availability; interferons β (IFN-β) and natalizumab were initially less used and then equally after some time; glatiramer acetate and fumarates were first used equally, then more frequently in women. The proportion of treated women, analyzed from the first childbirth of 5,268 women, began to decline 18 months before childbirth, from 42.6% to 27.9% at the estimated time of conception. DISCUSSION: Women with MS were significantly less exposed to DMTs compared with men. Anticipation of pregnancy was probably an important factor underlying this difference, but also sex-specific therapeutic inertia. Neurologists and patients should be educated on the most recent recommendations on the use of DMTs in the context of pregnancy to avoid deleterious therapeutic inertia.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 2025. PMID: 40737571. doi:10.1212/WNL.0000000000213907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。